{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,10,4]],"date-time":"2026-10-04T14:04:08Z","timestamp":1791122648582,"version":"4.1.0"},"reference-count":41,"publisher":"Springer Science and Business Media LLC","issue":"1","license":[{"start":{"date-parts":[[2025,4,4]],"date-time":"2025-04-04T00:00:00Z","timestamp":1743724800000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by-nc-nd\/4.0"},{"start":{"date-parts":[[2025,4,4]],"date-time":"2025-04-04T00:00:00Z","timestamp":1743724800000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by-nc-nd\/4.0"}],"funder":[{"name":"General Projects of the Young and Middle-aged Scientific Research Fund of Qinghai University Affiliated Hospital","award":["ASRF-2022-YB-12"],"award-info":[{"award-number":["ASRF-2022-YB-12"]}]},{"name":"the National Natural Science Foundation of China funded the article","award":["82060485"],"award-info":[{"award-number":["82060485"]}]},{"DOI":"10.13039\/501100011501","name":"Qinghai Provincial Department of Science and Technology","doi-asserted-by":"publisher","award":["2019-ZJ-7091"],"award-info":[{"award-number":["2019-ZJ-7091"]}],"id":[{"id":"10.13039\/501100011501","id-type":"DOI","asserted-by":"publisher"}]}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["BMC Women's Health"],"DOI":"10.1186\/s12905-025-03610-9","type":"journal-article","created":{"date-parts":[[2025,4,5]],"date-time":"2025-04-05T01:39:07Z","timestamp":1743817147000},"update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":5,"title":["Optimal extension time after initial endocrine therapy for postmenopausal hormone receptor-positive early-stage breast cancer: a systematic review and meta-analysis"],"prefix":"10.1186","volume":"25","author":[{"ORCID":"https:\/\/orcid.org\/0009-0000-7214-1978","authenticated-orcid":false,"given":"Zhang","family":"Ying","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0003-1998-5746","authenticated-orcid":false,"given":"Liu","family":"Linxun","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Zhao","family":"kechang","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Wang","family":"Xiaowu","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Gengzhi","family":"Huazhen","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0009-0006-9518-4288","authenticated-orcid":false,"given":"Ma","family":"Zhijun","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"297","published-online":{"date-parts":[[2025,4,4]]},"reference":[{"key":"3610_CR1","doi-asserted-by":"publisher","unstructured":"Bray F, Ferlay J, Soerjomataram I, et al. Global cancer statistics 2018: GLOBOCAN estimates of incidence and mortality worldwide for 36 cancers in 185 countries. CA\u00a0 Cancer J Clin. 2018;68(6):394\u2013424. https:\/\/doi.org\/10.3322\/caac.21492.","DOI":"10.3322\/caac.21492"},{"key":"3610_CR2","doi-asserted-by":"publisher","unstructured":"Sung H, Ferlay J, Siegel RL, et al. Global cancer statistics 2020: GLOBOCAN estimates of incidence and mortality worldwide for 36 cancers in 185 countries .CA Cancer J Clin. 2021;71( 3):209\u2013249. https:\/\/doi.org\/10.3322\/caac.21660.","DOI":"10.3322\/caac.21660"},{"key":"3610_CR3","doi-asserted-by":"publisher","unstructured":"Vici P, Pizzuti L, Natoli C, et al. Triple positive breast cancer: a distinct subtype?.Cancer Treat Rev. 2015;41( 2):69\u201376. https:\/\/doi.org\/10.1016\/j.ctrv.2014.12.005.","DOI":"10.1016\/j.ctrv.2014.12.005"},{"issue":"11","key":"3610_CR4","doi-asserted-by":"publisher","first-page":"1410","DOI":"10.1016\/j.annonc.2021.08.1988","volume":"32","author":"S Schrodi","year":"2021","unstructured":"Schrodi S, Braun M, Andrulat A, et al. Outcome of breast cancer patients with low hormone receptor positivity: analysis of a 15-year population-based cohort. Ann Oncol. 2021;32(11):1410\u201324. https:\/\/doi.org\/10.1016\/j.annonc.2021.08.1988.","journal-title":"Ann Oncol"},{"issue":"19","key":"3610_CR5","doi-asserted-by":"publisher","first-page":"3614","DOI":"10.1158\/0008-5472.CAN-22-0900","volume":"82","author":"E Zeng","year":"2022","unstructured":"Zeng E, He W, Sj\u00f6lander A, Bergqvist J, Czene K. Determinants and Effectiveness of Extending the Duration of Adjuvant Hormone Therapy beyond 5 Years in Patients with Breast Cancer. Cancer Res. 2022;82(19):3614\u201321. https:\/\/doi.org\/10.1158\/0008-5472.CAN-22-0900.","journal-title":"Cancer Res"},{"issue":"2","key":"3610_CR6","doi-asserted-by":"publisher","first-page":"320","DOI":"10.1210\/endrev\/bnz001","volume":"41","author":"B Trabert","year":"2020","unstructured":"Trabert B, Sherman ME, Kannan N, Stanczyk FZ. Progesterone and Breast Cancer. Endocr Rev. 2020;41(2):320\u201344. https:\/\/doi.org\/10.1210\/endrev\/bnz001.","journal-title":"Endocr Rev"},{"key":"3610_CR7","doi-asserted-by":"publisher","unstructured":"Early Breast Cancer Trialists\u2019 Collaborative Group (EBCTCG), Davies C, Godwin J, et al. Relevance of breast cancer hormone receptors and other factors to the efficacy of adjuvant tamoxifen: patient-level meta-analysis of randomised trials.\u00a0Lancet. 2011;378(9793):771\u2013784. https:\/\/doi.org\/10.1016\/S0140-6736(11)60993-8.","DOI":"10.1016\/S0140-6736(11)60993-8"},{"key":"3610_CR8","doi-asserted-by":"publisher","unstructured":"Early Breast Cancer Trialists\u2019 Collaborative Group (EBCTCG). Aromatase inhibitors versus tamoxifen in early breast cancer: patient-level meta-analysis of the randomised trials.\u00a0Lancet. 2015;386(10001):1341\u20131352. https:\/\/doi.org\/10.1016\/S1470-2045(21)00758-0.","DOI":"10.1016\/S1470-2045(21)00758-0"},{"issue":"12","key":"3610_CR9","doi-asserted-by":"publisher","first-page":"1135","DOI":"10.1016\/S1470-2045(10)70257-6","volume":"11","author":"J Cuzick","year":"2010","unstructured":"Cuzick J, Sestak I, Baum M, et al. Effect of anastrozole and tamoxifen as adjuvant treatment for early-stage breast cancer: 10-year analysis of the ATAC trial[J]. Lancet Oncol. 2010;11(12):1135\u201341. https:\/\/doi.org\/10.1016\/S1470-2045(10)70257-6.","journal-title":"Lancet Oncol"},{"key":"3610_CR10","doi-asserted-by":"publisher","unstructured":"Lee HJ, Park IA, Park SY, et al. Two histopathologically different diseases: hormone receptor-positive and hormone receptor-negative tumors in HER2-positive breast cancer. Breast Cancer Res Treat. 2014;145( 3):615\u2013623. https:\/\/doi.org\/10.1007\/s10549-014-2983-x.","DOI":"10.1007\/s10549-014-2983-x"},{"issue":"35","key":"3610_CR11","doi-asserted-by":"publisher","first-page":"3959","DOI":"10.1200\/JCO.21.01392","volume":"39","author":"HJ Burstein","year":"2021","unstructured":"Burstein HJ, Somerfield MR, Barton DL, et al. Endocrine Treatment and Targeted Therapy for Hormone Receptor-Positive, Human Epidermal Growth Factor Receptor 2-Negative Metastatic Breast Cancer: ASCO Guideline Update. J Clin Oncol. 2021;39(35):3959\u201377. https:\/\/doi.org\/10.1200\/JCO.21.01392.","journal-title":"J Clin Oncol"},{"issue":"1","key":"3610_CR12","doi-asserted-by":"publisher","first-page":"67","DOI":"10.1016\/S1470-2045(14)71171-4","volume":"16","author":"J Cuzick","year":"2015","unstructured":"Cuzick J, Sestak I, Cawthorn S, et al. Tamoxifen for prevention of breast cancer: extended long-term follow-up of the IBIS-I breast cancer prevention trial. Lancet Oncol. 2015;16(1):67\u201375. https:\/\/doi.org\/10.1016\/S1470-2045(14)71171-4.","journal-title":"Lancet Oncol"},{"key":"3610_CR13","doi-asserted-by":"publisher","unstructured":"Davie A, Carter GC, Rider A, et al. Real-world patient-reported outcomes of women receiving initial endocrine-based therapy for HR+\/HER2- advanced breast cancer in five European countries.\u00a0BMC Cancer. 2020;20(1):855. Published 2020 Sep 7. https:\/\/doi.org\/10.1186\/s12885-020-07294-2.","DOI":"10.1186\/s12885-020-07294-2"},{"key":"3610_CR14","doi-asserted-by":"publisher","unstructured":"Simon J, Chaix M, Billa O, et al. Survival in patients with HR+\/HER2- metastatic breast cancer treated with initial endocrine therapy versus initial chemotherapy. A French population-based study.\u00a0Br J Cancer. 2020;123(7):1071\u20131077. https:\/\/doi.org\/10.1038\/s41416-020-0979-3.","DOI":"10.1038\/s41416-020-0979-3"},{"issue":"3","key":"3610_CR15","doi-asserted-by":"publisher","first-page":"431","DOI":"10.1016\/j.jgo.2019.07.024","volume":"11","author":"HC Pieters","year":"2020","unstructured":"Pieters HC, Green E, Sleven M, Stanton AL. Aromatase inhibitors: The unexpected breast cancer treatment. J Geriatr Oncol. 2020;11(3):431\u20136. https:\/\/doi.org\/10.1016\/j.jgo.2019.07.024.","journal-title":"J Geriatr Oncol"},{"key":"3610_CR16","doi-asserted-by":"publisher","DOI":"10.1136\/bmj.n71","author":"MJ Page","year":"2020","unstructured":"Page MJ, McKenzie JE, Bossuyt PM, The PRISMA, et al. statement: an updated guideline for reporting systematic reviews. BMJ. 2020. https:\/\/doi.org\/10.1136\/bmj.n71.","journal-title":"BMJ"},{"key":"3610_CR17","doi-asserted-by":"publisher","first-page":"177","DOI":"10.1016\/0197-2456(86)90046-2","volume":"7","author":"R Der Simonian","year":"1986","unstructured":"Der Simonian R, Laird N. Meta-analysis in clinical trials. Control Clin Trials. 1986;7:177.","journal-title":"Control Clin Trials"},{"key":"3610_CR18","doi-asserted-by":"publisher","first-page":"629","DOI":"10.1136\/bmj.315.7109.629","volume":"315","author":"M Egger","year":"1997","unstructured":"Egger M, Davey Smith G, Schneider M, Minder C. Bias in meta-analysis detected by a simple, graphical test. BMJ. 1997;315:629. https:\/\/doi.org\/10.1136\/bmj.315.7109.629.","journal-title":"BMJ"},{"issue":"19","key":"3610_CR19","doi-asserted-by":"publisher","first-page":"1836","DOI":"10.1056\/NEJMoa1701830","volume":"377","author":"H Pan","year":"2017","unstructured":"Pan H, Gray R, Braybrooke J, et al. 20-year risks of breast-cancer recurrence after stopping endocrine therapy at 5 years[J]. N Engl J Med. 2017;377(19):1836\u201346. https:\/\/doi.org\/10.1056\/NEJMoa1701830.","journal-title":"N Engl J Med"},{"key":"3610_CR20","doi-asserted-by":"publisher","unstructured":"Bradley R, Braybrooke J, Gray R, et al. Aromatase inhibitors versus tamoxifen in premenopausal women with oestrogen receptor-positive early-stage breast cancer treated with ovarian suppression: a patient-level meta-analysis of 7030 women from four randomised trials. Lancet Oncol. 2022;23(3):382\u2013392. https:\/\/doi.org\/10.1016\/S1470-2045(21)00758-0.","DOI":"10.1016\/S1470-2045(21)00758-0"},{"key":"3610_CR21","doi-asserted-by":"publisher","unstructured":"Davies C, Pan H, Godwin J, et al. Long-term effects of continuing adjuvant tamoxifen to 10 years versus stopping at 5 years after diagnosis of oestrogen receptor-positive breast cancer: ATLAS, a randomised trial [published correction appears in Lancet. 2013;381(9869):804] [published correction appears in Lancet. 2017;389(10082):1884]. Lancet.2013;381(9869):805\u2013816. https:\/\/doi.org\/10.1016\/S0140-6736(12)61963-1.","DOI":"10.1016\/S0140-6736(12)61963-1"},{"issue":"9","key":"3610_CR22","doi-asserted-by":"publisher","first-page":"684","DOI":"10.1093\/jnci\/93.9.684","volume":"93","author":"B Fisher","year":"2001","unstructured":"Fisher B, Dignam J, Bryant J, et al. Five versus more than five years of tamoxifen for lymph node-negative breast cancer: updated findings from the National Surgical Adjuvant Breast and Bowel Project B-14 randomized trial[J]. J Natl Cancer Inst. 2001;93(9):684\u201390. https:\/\/doi.org\/10.1093\/jnci\/93.9.684.","journal-title":"J Natl Cancer Inst"},{"issue":"12","key":"3610_CR23","doi-asserted-by":"publisher","first-page":"1965","DOI":"10.1200\/JCO.2007.14.0228","volume":"26","author":"EP Mamounas","year":"2008","unstructured":"Mamounas EP, Jeong JH, Wickerham DL, et al. Benefit from exemestane as extended adjuvant therapy after 5 years of adjuvant tamoxifen: intention-to-treat analysis of the National Surgical Adjuvant Breast And Bowel Project B-33 trial. J Clin Oncol. 2008;26(12):1965\u201371. https:\/\/doi.org\/10.1200\/JCO.2007.14.0228.","journal-title":"J Clin Oncol"},{"key":"3610_CR24","doi-asserted-by":"publisher","unstructured":"Tjan-Heijnen VCG, van Hellemond IEG, Peer PGM, et al. Extended adjuvant aromatase inhibition after sequential endocrine therapy (DATA): a randomised, phase 3 trial [published correction appears in Lancet Oncol. 2017;18(11):e642]. Lancet Oncol. 2017;18(11):1502\u20131511. https:\/\/doi.org\/10.1016\/S1470-2045(17)30600-9.","DOI":"10.1016\/S1470-2045(17)30600-9"},{"issue":"16","key":"3610_CR25","doi-asserted-by":"publisher","first-page":"5671","DOI":"10.1158\/1078-0432.CCR-05-0354","volume":"11","author":"BS Mann","year":"2005","unstructured":"Mann BS, Johnson JR, Kelly R, Sridhara R, Williams G, Pazdur R. Letrozole in the extended adjuvant treatment of postmenopausal women with history of early-stage breast cancer who have completed 5 years of adjuvant tamoxifen. Clin Cancer Res. 2005;11(16):5671\u20137. https:\/\/doi.org\/10.1158\/1078-0432.CCR-05-0354.","journal-title":"Clin Cancer Res"},{"key":"3610_CR26","doi-asserted-by":"publisher","unstructured":"Goss PE, Ingle JN, Martino S, et al. Randomized trial of letrozole following tamoxifen as extended adjuvant therapy in receptor-positive breast cancer: updated findings from NCIC CTG MA.17.\u00a0J Natl Cancer Inst. 2005;97(17):1262\u20131271. https:\/\/doi.org\/10.1093\/jnci\/dji250.","DOI":"10.1093\/jnci\/dji250"},{"key":"3610_CR27","doi-asserted-by":"publisher","unstructured":"Li L, Chang B, Jiang X, et al. Clinical outcomes comparison of 10 years versus 5 years of adjuvant endocrine therapy in patients with early breast cancer. BMC Cancer. 2018;18(1):977. Published 2018 Oct 12. https:\/\/doi.org\/10.1186\/s12885-018-4878-4.","DOI":"10.1186\/s12885-018-4878-4"},{"issue":"10","key":"3610_CR28","doi-asserted-by":"publisher","first-page":"1458","DOI":"10.1016\/S1470-2045(21)00352-1","volume":"22","author":"L Del Mastro","year":"2021","unstructured":"Del Mastro L, Mansutti M, Bisagni G, et al. Extended therapy with letrozole as adjuvant treatment of postmenopausal patients with early-stage breast cancer: a multicentre, open-label, randomised, phase 3 trial. Lancet Oncol. 2021;22(10):1458\u201367. https:\/\/doi.org\/10.1016\/S1470-2045(21)00352-1.","journal-title":"Lancet Oncol"},{"issue":"5","key":"3610_CR29","doi-asserted-by":"publisher","first-page":"395","DOI":"10.1056\/NEJMoa2104162","volume":"385","author":"M Gnant","year":"2021","unstructured":"Gnant M, Fitzal F, Rinnerthaler G, et al. Duration of Adjuvant Aromatase-Inhibitor Therapy in Postmenopausal Breast Cancer. N Engl J Med. 2021;385(5):395\u2013405. https:\/\/doi.org\/10.1056\/NEJMoa2104162.","journal-title":"N Engl J Med"},{"key":"3610_CR30","doi-asserted-by":"publisher","unstructured":"Blok EJ, Kroep JR, Meershoek-Klein Kranenbarg E, et al. Optimal Duration of Extended Adjuvant Endocrine Therapy for Early Breast Cancer; Results of the IDEAL Trial (BOOG 2006\u201305).\u00a0J Natl Cancer Inst. 2018;110(1):https:\/\/doi.org\/10.1093\/jnci\/djx134. https:\/\/doi.org\/10.1093\/jnci\/djx134.","DOI":"10.1093\/jnci\/djx134 10.1093\/jnci\/djx134"},{"issue":"5","key":"3610_CR31","doi-asserted-by":"publisher","first-page":"296","DOI":"10.1038\/s41571-018-0145-5","volume":"16","author":"J Richman","year":"2019","unstructured":"Richman J, Dowsett M. Beyond 5 years: enduring risk of recurrence in oestrogen receptor-positive breast cancer. Nat Rev Clin Oncol. 2019;16(5):296\u2013311. https:\/\/doi.org\/10.1038\/s41571-018-0145-5.","journal-title":"Nat Rev Clin Oncol"},{"key":"3610_CR32","doi-asserted-by":"publisher","unstructured":"Barron TI, Connolly R, Bennett K, et al. Early discontinuation of tamoxifen: a lesson for oncologists. Cancer: Interdisciplinary Int J Am Cancer Soc. 2007;109(5):832\u2013839.\u00a0https:\/\/doi.org\/10.1002\/cncr.22485.","DOI":"10.1002\/cncr.22485"},{"issue":"1\u20132","key":"3610_CR33","doi-asserted-by":"publisher","first-page":"1","DOI":"10.1159\/000100444","volume":"71","author":"RT Chlebowski","year":"2006","unstructured":"Chlebowski RT, Geller ML. Adherence to endocrine therapy for breast cancer[J]. Oncology. 2006;71(1\u20132):1\u20139.","journal-title":"Oncology"},{"key":"3610_CR34","doi-asserted-by":"publisher","unstructured":"Goldvaser H, Barnes T A, \u0160eruga B, et al. Toxicity of extended adjuvant therapy with aromatase inhibitors in early breast cancer: a systematic review and meta-analysis. JNCI: J Natl Cancer Instit. 2018, 110(1): 31\u201339. https:\/\/doi.org\/10.1093\/jnci\/djx141.","DOI":"10.1093\/jnci\/djx141"},{"key":"3610_CR35","doi-asserted-by":"publisher","first-page":"209","DOI":"10.1056\/NEJMoa1604700","volume":"375","author":"PE Goss","year":"2016","unstructured":"Goss PE, Ingle JN, Pritchard KI, et al. Extending aromatase-inhibitor adjuvant therapy to 10 years[J]. N Engl J Med. 2016;375:209\u201319. https:\/\/doi.org\/10.1056\/NEJMoa1604700.","journal-title":"N Engl J Med"},{"issue":"10218","key":"3610_CR36","doi-asserted-by":"publisher","first-page":"117","DOI":"10.1016\/S0140-6736(19)32955-1","volume":"395","author":"J Cuzick","year":"2020","unstructured":"Cuzick J, Sestak I, Forbes JF, Dowsett M, Cawthorn S, Mansel RE, Loibl S, Bonanni B, Evans DG, Howell A, IBIS-II investigators,. Use of anastrozole for breast cancer prevention (IBIS-II): long-term results of a randomised controlled trial. Lancet (London, England). 2020;395(10218):117\u201322. https:\/\/doi.org\/10.1016\/S0140-6736(19)32955-1.","journal-title":"Lancet (London, England)"},{"key":"3610_CR37","doi-asserted-by":"publisher","unstructured":"Stearns V, Chapman JA, Ma CX, et al. Treatment-associated musculoskeletal and vasomotor symptoms and relapse-free survival in the NCIC CTG MA.27 adjuvant breast cancer aromatase inhibitor trial.\u00a0J Clin Oncol. 2015;33(3):265\u2013271. https:\/\/doi.org\/10.1200\/JCO.2014.57.6926.","DOI":"10.1200\/JCO.2014.57.6926"},{"key":"3610_CR38","doi-asserted-by":"publisher","first-page":"8","DOI":"10.1016\/j.breast.2021.05.013","volume":"59","author":"C Villarreal-Garza","year":"2021","unstructured":"Villarreal-Garza C, Mesa-Chavez F, Ferrigno AS, et al. Adjuvant endocrine therapy for premenopausal women with breast cancer: Patient adherence and physician prescribing practices in Mexico. Breast. 2021;59:8\u201315. https:\/\/doi.org\/10.1016\/j.breast.2021.05.013.","journal-title":"Breast"},{"issue":"1","key":"3610_CR39","doi-asserted-by":"publisher","first-page":"1","DOI":"10.1007\/s10330-009-0188-2","volume":"9","author":"S Yu","year":"2010","unstructured":"Yu S, Jiang Z, Zhang L, et al. Chinese expert consensus statement on clinical diagnosis and treatment of malignant tumor bone metastasis and bone related diseases[J]. Chin-Ger J Clin Oncol. 2010;9(1):1\u201312.","journal-title":"Chin-Ger J Clin Oncol"},{"key":"3610_CR40","doi-asserted-by":"publisher","first-page":"155","DOI":"10.1016\/j.jsbmb.2013.09.008","volume":"142","author":"SH Tella","year":"2014","unstructured":"Tella SH, Gallagher JC. Prevention and treatment of postmenopausal osteoporosis. J Steroid Biochem Mol Biol. 2014;142:155\u201370. https:\/\/doi.org\/10.1016\/j.jsbmb.2013.09.008.","journal-title":"J Steroid Biochem Mol Biol"},{"issue":"6","key":"3610_CR41","first-page":"243","volume":"33","author":"S Vinayak","year":"2019","unstructured":"Vinayak S, Davidson NE. Extending Adjuvant Endocrine Therapy in Breast Cancer: Who, What, Why? Oncology (Williston Park). 2019;33(6):243\u20136.","journal-title":"Oncology (Williston Park)"}],"container-title":["BMC Women's Health"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1186\/s12905-025-03610-9.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/article\/10.1186\/s12905-025-03610-9\/fulltext.html","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1186\/s12905-025-03610-9.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2025,4,5]],"date-time":"2025-04-05T01:39:09Z","timestamp":1743817149000},"score":1,"resource":{"primary":{"URL":"https:\/\/bmcwomenshealth.biomedcentral.com\/articles\/10.1186\/s12905-025-03610-9"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2025,4,4]]},"references-count":41,"journal-issue":{"issue":"1","published-online":{"date-parts":[[2025,12]]}},"alternative-id":["3610"],"URL":"https:\/\/doi.org\/10.1186\/s12905-025-03610-9","relation":{},"ISSN":["1472-6874"],"issn-type":[{"value":"1472-6874","type":"electronic"}],"subject":[],"published":{"date-parts":[[2025,4,4]]},"assertion":[{"value":"19 December 2023","order":1,"name":"received","label":"Received","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"16 February 2025","order":2,"name":"accepted","label":"Accepted","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"4 April 2025","order":3,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}},{"order":1,"name":"Ethics","group":{"name":"EthicsHeading","label":"Declarations"}},{"value":"Not applicable.","order":2,"name":"Ethics","group":{"name":"EthicsHeading","label":"Ethics approval and consent to participate"}},{"value":"The authors declare no competing interests.","order":3,"name":"Ethics","group":{"name":"EthicsHeading","label":"Competing interests"}}],"article-number":"156"}}